comparemela.com
Home
Live Updates
Factor XIa Inhibitor Encouraging in Phase 2 MI, Stroke Studies : comparemela.com
Factor XIa Inhibitor Encouraging in Phase 2 MI, Stroke Studies
It's all exploratory, but asundexian given with antiplatelets showed safe nuanced potential against poststroke recurrent events and quashed circulating factor XIa after stenting for acute MI.
Related Keywords
Boston
,
Massachusetts
,
United States
,
Boston University
,
Canada
,
North Carolina
,
United Kingdom
,
Spain
,
Barcelona
,
Comunidad Autonoma De Cataluna
,
Ashkan Shoamanesh
,
Artivion Cryolife
,
Bristol Myers Squibb
,
Glaxosmithkline
,
Amgen
,
Mcmaster University
,
Boehringer Ingelheim
,
Boston University School Of Medicine
,
Duke Clinical Research Institute
,
University Of Liverpool
,
Novartis
,
Pfizer
,
European Society Of Cardiology
,
Janssen Pharmaceuticals
,
Medtronic
,
European Society
,
Medscape Cardiology
,
Boston University School
,
Anthos Therapeutics
,
Hot Line Session
,
Cv
,
Ardiovascular
,
Anticoagulation Therapy
,
Anticoagulant
,
Anticoagulation
,
Antiplatelet Agent
,
Myocardial Infarction
,
Embolic Stroke
,
Hemorrhage
,
Bleeding
,
Antithrombotics
,
Anti Thrombotics
,
Antithrombotic Therapy
,
Antithrombotic Agents
,
comparemela.com © 2020. All Rights Reserved.